The hMLH1 −93G>A Promoter Polymorphism is Associates with Outcomes in Oral Squamous Cell Carcinoma Patients

Li Han Lin; Ming Wei Lin; Kwei Mar; Chun Shu Lin; Dar Der Ji; Wei Ping Lee; Herng Sheng Lee; Ming Fang Cheng; Kan Tai Hsia

doi:10.1245/s10434-014-3897-x

The hMLH1 −93G>A Promoter Polymorphism is Associates with Outcomes in Oral Squamous Cell Carcinoma Patients

Li Han Lin, Ming Wei Lin, Kwei Mar, Chun Shu Lin, Dar Der Ji, Wei Ping Lee, Herng Sheng Lee, Ming Fang Cheng, Kan Tai Hsia^*

^*此作品的通信作者

研究成果: Article › 同行評審

5 引文斯高帕斯（Scopus）

摘要

Background: The aim of this study was to investigate the impact of hMLH1 polymorphisms on treatment outcomes in patients with oral squamous cell carcinoma (OSCC).

Methods: Genotypings were performed by direct DNA sequencing in peripheral blood leukocytes from 185 male OSCC patients. Patients received primary surgery with or without adjuvant radiotherapy. Two hMLH1 tag single nucleotide polymorphisms (SNPs)—rs1800734 (−93G>A in the promoter) and rs1540354 (in the third intron)—were chosen from the HapMap project. Overall survival (OS) and disease-free survival (DFS) were compared between different genotypes.

Results: The hMLH1 rs1800734 and rs1540354 polymorphisms were in weak linkage disequilibrium (r² = 0.456). OSCC patients with the rs1800734 AA genotype had a significantly poor prognosis in both OS and DFS. This SNP can also predict the outcomes of OSCC patients with postoperative adjuvant radiotherapy, especially in advanced stage; however, no significant differences in patient outcomes were found for the hMLH1 rs1540354 genotypes.

Conclusions: Our results demonstrate that the hMLH1 −93G>A SNP is found to be associated with patient outcomes in OSCC. This SNP can also predict their treatment outcome of radiotherapy.

原文	English
頁（從 - 到）	4270-4277
頁數	8
期刊	Annals of Surgical Oncology
卷	21
發行號	13
DOIs	https://doi.org/10.1245/s10434-014-3897-x
出版狀態	Published - 31 10月 2014

存取文件

10.1245/s10434-014-3897-x

其它文件與鏈接

Link to publication in Scopus

引用此

@article{04baa098d5fa4bafb9678c726935b57f,

title = "The hMLH1 −93G>A Promoter Polymorphism is Associates with Outcomes in Oral Squamous Cell Carcinoma Patients",

abstract = "Background: The aim of this study was to investigate the impact of hMLH1 polymorphisms on treatment outcomes in patients with oral squamous cell carcinoma (OSCC).Methods: Genotypings were performed by direct DNA sequencing in peripheral blood leukocytes from 185 male OSCC patients. Patients received primary surgery with or without adjuvant radiotherapy. Two hMLH1 tag single nucleotide polymorphisms (SNPs)—rs1800734 (−93G>A in the promoter) and rs1540354 (in the third intron)—were chosen from the HapMap project. Overall survival (OS) and disease-free survival (DFS) were compared between different genotypes.Results: The hMLH1 rs1800734 and rs1540354 polymorphisms were in weak linkage disequilibrium (r2 = 0.456). OSCC patients with the rs1800734 AA genotype had a significantly poor prognosis in both OS and DFS. This SNP can also predict the outcomes of OSCC patients with postoperative adjuvant radiotherapy, especially in advanced stage; however, no significant differences in patient outcomes were found for the hMLH1 rs1540354 genotypes.Conclusions: Our results demonstrate that the hMLH1 −93G>A SNP is found to be associated with patient outcomes in OSCC. This SNP can also predict their treatment outcome of radiotherapy.",

author = "Lin, {Li Han} and Lin, {Ming Wei} and Kwei Mar and Lin, {Chun Shu} and Ji, {Dar Der} and Lee, {Wei Ping} and Lee, {Herng Sheng} and Cheng, {Ming Fang} and Hsia, {Kan Tai}",

note = "Publisher Copyright: {\textcopyright} 2014, Society of Surgical Oncology.",

year = "2014",

month = oct,

day = "31",

doi = "10.1245/s10434-014-3897-x",

language = "English",

volume = "21",

pages = "4270--4277",

journal = "Annals of Surgical Oncology",

issn = "1068-9265",

publisher = "Springer New York",

number = "13",

}

TY - JOUR

T1 - The hMLH1 −93G>A Promoter Polymorphism is Associates with Outcomes in Oral Squamous Cell Carcinoma Patients

AU - Lin, Li Han

AU - Lin, Ming Wei

AU - Mar, Kwei

AU - Lin, Chun Shu

AU - Ji, Dar Der

AU - Lee, Wei Ping

AU - Lee, Herng Sheng

AU - Cheng, Ming Fang

AU - Hsia, Kan Tai

PY - 2014/10/31

Y1 - 2014/10/31

N2 - Background: The aim of this study was to investigate the impact of hMLH1 polymorphisms on treatment outcomes in patients with oral squamous cell carcinoma (OSCC).Methods: Genotypings were performed by direct DNA sequencing in peripheral blood leukocytes from 185 male OSCC patients. Patients received primary surgery with or without adjuvant radiotherapy. Two hMLH1 tag single nucleotide polymorphisms (SNPs)—rs1800734 (−93G>A in the promoter) and rs1540354 (in the third intron)—were chosen from the HapMap project. Overall survival (OS) and disease-free survival (DFS) were compared between different genotypes.Results: The hMLH1 rs1800734 and rs1540354 polymorphisms were in weak linkage disequilibrium (r2 = 0.456). OSCC patients with the rs1800734 AA genotype had a significantly poor prognosis in both OS and DFS. This SNP can also predict the outcomes of OSCC patients with postoperative adjuvant radiotherapy, especially in advanced stage; however, no significant differences in patient outcomes were found for the hMLH1 rs1540354 genotypes.Conclusions: Our results demonstrate that the hMLH1 −93G>A SNP is found to be associated with patient outcomes in OSCC. This SNP can also predict their treatment outcome of radiotherapy.

AB - Background: The aim of this study was to investigate the impact of hMLH1 polymorphisms on treatment outcomes in patients with oral squamous cell carcinoma (OSCC).Methods: Genotypings were performed by direct DNA sequencing in peripheral blood leukocytes from 185 male OSCC patients. Patients received primary surgery with or without adjuvant radiotherapy. Two hMLH1 tag single nucleotide polymorphisms (SNPs)—rs1800734 (−93G>A in the promoter) and rs1540354 (in the third intron)—were chosen from the HapMap project. Overall survival (OS) and disease-free survival (DFS) were compared between different genotypes.Results: The hMLH1 rs1800734 and rs1540354 polymorphisms were in weak linkage disequilibrium (r2 = 0.456). OSCC patients with the rs1800734 AA genotype had a significantly poor prognosis in both OS and DFS. This SNP can also predict the outcomes of OSCC patients with postoperative adjuvant radiotherapy, especially in advanced stage; however, no significant differences in patient outcomes were found for the hMLH1 rs1540354 genotypes.Conclusions: Our results demonstrate that the hMLH1 −93G>A SNP is found to be associated with patient outcomes in OSCC. This SNP can also predict their treatment outcome of radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84911959680&partnerID=8YFLogxK

U2 - 10.1245/s10434-014-3897-x

DO - 10.1245/s10434-014-3897-x

M3 - Article

C2 - 25047469

AN - SCOPUS:84911959680

SN - 1068-9265

VL - 21

SP - 4270

EP - 4277

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

IS - 13

ER -

The hMLH1 −93G>A Promoter Polymorphism is Associates with Outcomes in Oral Squamous Cell Carcinoma Patients

摘要

存取文件

其它文件與鏈接

指紋

引用此